RESUMEN
We have treated twelve patients with simvastatin: six had type IIA hypercholesterolaemia and the other six had type IIB. These patients have been examined before and after therapy, by an ophthalmologist. After therapy, the levels of the total cholesterol and triglycerides were decreased while HDL cholesterol was increased. Untoward side effects of ophthalmologic alterations were not observed.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Hipercolesterolemia/tratamiento farmacológico , Lovastatina/análogos & derivados , Anciano , Anticolesterolemiantes/efectos adversos , Presión Sanguínea/efectos de los fármacos , Colesterol/sangre , Evaluación de Medicamentos , Ojo/efectos de los fármacos , Femenino , Humanos , Hipercolesterolemia/sangre , Hiperlipoproteinemia Tipo II/sangre , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Lovastatina/efectos adversos , Lovastatina/uso terapéutico , Masculino , Persona de Mediana Edad , Simvastatina , Triglicéridos/sangreRESUMEN
The authors tested the efficacy of three different lipid-lowering drugs in subjects with more or less severe alterations of the lipoprotein pattern. All subjects were submitted to blood tests prior to and at the end of treatment with special attention to the trend of the lipid pattern, assaying cholesterol, HDL, LDL, triglyceride, total lipid blood levels and lipid electrophoresis. The drugs employed were: pantothenic acid, sulodexide, and DEAE-dextran.